



April 23, 2015

BioCryst to Announce First Quarter 2015 Financial Results May 8

RESEARCH TRIANGLE PARK, N.C., April 23, 2015 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq:BCRX) today announced that its first quarter 2015 financial results will be released on Friday, May 8, 2015. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company's programs. The call will be led by [Jon P. Stonehouse](#), President and Chief Executive Officer, [Thomas R. Staab, II](#), Senior Vice President and Chief Financial Officer and [Dr. William P. Sheridan](#), Senior Vice President and Chief Medical Officer.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including [BCX4161](#), [BCX7353](#) and other second generation compounds, and [BCX4430](#), a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com. In December 2014, [RAPIVAB](#)TM (peramivir injection), a viral neuraminidase inhibitor, was approved by the FDA. For more information regarding RAPIVAB, please visit <http://rapivab.com/>.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910



Source: BioCryst Pharmaceuticals

News Provided by Acquire Media